These three cancer stocks have tremendous upside potential.
News & Analysis: Exelixis
Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.
Looking for potential winning biotech stocks? These five check off all the boxes for investors.
If you're looking to buy biotech stocks, put these at the top of your list.
In a multibillion dollar cancer-treatment market, a solid second isn't too shabby.
EXEL earnings call for the period ending December 31, 2018.
With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.
A third-quarter earnings surprise and a European approval gave the stock some lift.
Growth at a reasonable price? You bet!
Liver cancer treatment is next on the biotech's checklist.